Fortitude Advisory Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.44M Buy
5,707
+521
+10% +$112K 0.55% 37
2026
Q1
$1.13M Buy
5,186
+90
+2% +$20K 0.51% 38
2025
Q4
$1.16M Sell
5,096
-58
-1% -$13.2K 0.49% 33
2025
Q3
$1.19M Sell
5,154
-37
-0.7% -$7.54K 0.64% 28
2025
Q2
$964K Sell
5,191
-24
-0.5% -$4.46K 0.55% 34
2025
Q1
$895K Buy
5,215
+109
+2% +$21.2K 0.64% 28
2024
Q4
$907K Buy
5,106
+41
+0.8% +$7.54K 0.55% 31
2024
Q3
$1M Sell
5,065
-188
-4% -$35.1K 0.63% 27
2024
Q2
$901K Sell
5,253
-402
-7% -$66.6K 0.54% 31
2024
Q1
$1.03M Sell
5,655
-150
-3% -$25.9K 0.58% 25
2023
Q4
$900K Buy
5,805
+171
+3% +$24.9K 0.55% 34
2023
Q3
$840K Buy
5,634
+962
+21% +$141K 0.57% 33
2023
Q2
$629K Sell
4,672
-530
-10% -$77.7K 0.46% 48
2023
Q1
$829K Buy
5,202
+113
+2% +$17.3K 0.64% 32
2022
Q4
$822K Buy
5,089
+172
+3% +$26.4K 0.7% 32
2022
Q3
$660K Buy
4,917
+841
+21% +$121K 0.63% 39
2022
Q2
$624K Sell
4,076
-2,728
-40% -$417K 0.57% 44
2022
Q1
$1.1M Buy
6,804
+129
+2% +$18.7K 0.59% 21
2021
Q4
$904K Buy
+6,675
New +$788K 0.45% 37

Other funds holding ABBV

Fortitude Advisory Group's ABBV Position: Q2 2026 in Review

Fortitude Advisory Group increased its AbbVie (ABBV) stake by 10% in Q2 2026, buying an estimated $112K and bringing the position to 5,707 shares worth $1.44M. The position accounts for 0.55% of the portfolio, ranked #37.

Fortitude Advisory Group first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 1,758 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Fortitude Advisory Group held 5,707 shares of AbbVie worth $1.44M as of Q2 2026.
  • Fortitude Advisory Group bought 521 AbbVie shares in Q2 2026, an estimated $112K.
  • AbbVie made up 0.55% of Fortitude Advisory Group's portfolio in Q2 2026, its #37 holding.
  • Fortitude Advisory Group first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 1,758 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fortitude Advisory Group's 13F filing for Q2 2026, filed 22 Jul 2026.